Integrating APOL1 Kidney-risk Variant Testing in Live Kidney Donor Evaluation: An Expert Panel Opinion

Transplantation. 2021 Oct 1;105(10):2132-2134. doi: 10.1097/TP.0000000000003641.

Authors

Mona D Doshi¹, Elisa J Gordon², Barry I Freedman³, Craig Glover⁴, Jayme E Locke⁵, Christie P Thomas^{6

6}

Affiliations

¹ Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, MI.
² Department of Surgery-Transplantation, Northwestern University, Chicago, IL.
³ Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC.
⁴ Miami, FL.
⁵ Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
⁶ Department of Medicine, University of Iowa, Iowa City, IA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Apolipoprotein L1 / genetics*
Black People / genetics*
Clinical Decision-Making
Donor Selection*
Genetic Testing*
Genetic Variation*
Graft Survival
Humans
Kidney Failure, Chronic / diagnosis
Kidney Failure, Chronic / ethnology
Kidney Failure, Chronic / genetics*
Kidney Transplantation* / adverse effects
Living Donors*
Predictive Value of Tests
Risk Assessment
Risk Factors
Treatment Outcome

Substances

APOL1 protein, human
Apolipoprotein L1

Grants and funding